AlphAIalphai — Financial news for AI agents
TradingView — Track All MarketsAPR 142 min read$DMAC

EBITDA per share of DiaMedica Therapeutics Inc. – NASDAQ:DMAC

This article provides the EBITDA per share information for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). The content appears to be a financial data snippet from TradingView, focusing on key financial metrics for the specified biotechnology company.

Original reporting
TradingView — Track All Markets
Published Apr 14, 2026, 8:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 14, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
EBITDA per share of DiaMedica Therapeutics Inc. – NASDAQ:DMAC — source image
Source · TradingView — Track All Markets
Decision brief

The 30-second read

$DMACNeutralLow
01

Why it matters

The current EBITDA per share suggests stable operations but does not signal immediate growth or decline. Investors should consider additional financial metrics and news catalysts for comprehensive analysis.

02

Market read

The EBITDA data provides limited immediate trading signals but contributes to overall financial assessment.

03

What to watch

Market-wide liquidity conditions and broader biotech sector trends could influence DMAC's stock performance beyond EBITDA metrics.

Timing: short-term

Background

DiaMedica Therapeutics Inc. operates in the biotechnology sector, focusing on developing treatments for neurological and kidney diseases. EBITDA per share is a key financial metric indicating operational efficiency.

Company-level read

Ticker impact

$DMACNeutralMedium confidence
Context

Financial metric focus on EBITDA per share for DiaMedica Therapeutics Inc.

Expected impact

Minimal short-term price movement; likely to trade within recent ranges.

Evidence & confidence

The EBITDA per share data provides insight into operational efficiency but lacks context on revenue growth, profitability trends, or industry benchmarks. The neutral sentiment and absence of significant news suggest limited immediate impact.

Market effects

Sector

Biotechnology sector may experience slight stability; no significant sector-wide shifts expected.

Regional

Limited regional impact; company-specific data dominates.

Global

Minimal; DiaMedica is a smaller biotech firm with limited global influence.

Counterpoint

What could challenge this read

If upcoming clinical trial results or partnership news emerge, the stock could experience upward movement, making it a potential swing trade opportunity.

Key entities

  • Company
    DiaMedica Therapeutics Inc.

    A biotechnology company focused on neurological and kidney disease treatments.

Read at source← All news

Related articles

AUG 10
$DMACMed

DiaMedica Therapeutics Inc. (DMAC): Results of Operations and Financial Condition

DiaMedica Therapeutics Inc. (DMAC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1001907.htm EXHIBIT 99.1 ex_1001907.htm Exhibit 99.1 DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights ● Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader

SEC EDGAR 8-K6 min
AUG 11
$CCEYFMedAI 8/10

CanCambria Energy Provides Updated Contingent Resource Evaluation for Flagship Deep Gas Project, Attributable to Strong European Natural Gas Prices, Driving an Increased NPV10 of US$2.04 Billion

CanCambria Energy Corp. (TSXV: CCEC) reported an updated independent contingent resource evaluation for its 100% owned Kiskunhalas deep gas project in southern Hungary. Prepared by CHPE (effective June 30, 2026), it assumes $12.00/MMBtu TTF1 gas. Risked 2C Development Pending NPV10 rose 16% to US$2.04B from US$1.762B; 2C volumes are 571.9 Bcf and 59.6 MMbbl. First gas is targeted for mid-2027.

oilandgas360.com4 min
AUG 10
$NVDAMed

Nvidia partners with lenders to finance AI infrastructure

Nvidia said it will partner with a lender consortium including Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs and KKR to create financing vehicles totaling more than $500 billion for AI infrastructure. Nvidia links the plan to customer access to compute and its DSX datacenter design. The company has recently backstopped customer lending and used its balance sheet for deals such as with OpenAI. Nvidia shares fell on the news.

yahoo.com4 min
AUG 10
$ONDSMed

Dzyne gets $6M Air Force Contract

Dzyne Technologies, an Irvine-based unit of Ondas Technologies, received a $6 million U.S. Air Force contract to develop the Long-Range Grasshopper aerial delivery system, according to Ondas. The system targets extended-range logistics in contested and austere environments. Ondas said the work will be integrated into its Ondas Sentinel platform.

ocbj.com2 min
AUG 10
$FRMIMedAI 8/10

Why is Fermi America stock surging today?

Investing.com reports Fermi America LLC shares rose 29.9% in after-hours after announcing its first binding customer lease for Project Matador in Texas. The 15-year deal with TensorWave TEX1, LLC covers 222 MW and is expected to generate about $6.5B in contracted revenue, with deliveries starting in phases in H2 2027.

investing.com4 min